1-3 of 3
Albert Yu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Clinical Trials & Observations
Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven E. Coutre, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert Yu, Wayne R. Godfrey, Nina D. Wagner-Johnston
Journal: Blood
Blood (2014) 123 (22): 3398–3405.
https://doi.org/10.1182/blood-2013-11-537555
Published: 2014
Journal Articles

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Julia Hoellenriegel, Sarah A. Meadows, Mariela Sivina, William G. Wierda, Hagop Kantarjian, Michael J. Keating, Neill Giese, Susan O'Brien, Albert Yu, Langdon L. Miller, Brian J. Lannutti, Jan A. Burger
Journal: Blood
Blood (2011) 118 (13): 3603–3612.
https://doi.org/10.1182/blood-2011-05-352492
Published: 2011
Includes: Supplemental data
Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese
Journal: Blood
Blood (2008) 112 (11): 16.
https://doi.org/10.1182/blood.V112.11.16.16
Published: 2008